153 related articles for article (PubMed ID: 31197205)
21. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
[TBL] [Abstract][Full Text] [Related]
22. [Effect of
Yuan J; Han H; Dong W; Wang RC; Hao HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):96-103. PubMed ID: 36765483
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
[TBL] [Abstract][Full Text] [Related]
24. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
26. High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.
Breinholt MF; Oliveira DVNP; Klausen TW; Gang AO; Schejbel L; Pedersen MØ; Elbaek MV; Clasen-Linde E; Nielsen SL; Knudsen H; Høgdall E; Nørgaard P
Hematol Oncol; 2021 Aug; 39(3):284-292. PubMed ID: 33480087
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
28. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
29. Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma.
Yan S; Shang Q; Fan Z; Yang Y; Liu Y; Gao H; Chen K; Liang F; Li X; Zhang Q; Yan H
J Immunol Res; 2022; 2022():5633096. PubMed ID: 36213322
[TBL] [Abstract][Full Text] [Related]
30. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
32. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Battistello E; Katanayeva N; Dheilly E; Tavernari D; Donaldson MC; Bonsignore L; Thome M; Christie AL; Murakami MA; Michielin O; Ciriello G; Zoete V; Oricchio E
Blood; 2018 May; 131(21):2345-2356. PubMed ID: 29567799
[TBL] [Abstract][Full Text] [Related]
33. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
34. Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.
Bogusz AM; Kovach AE; Le LP; Feng D; Baxter RH; Sohani AR
PLoS One; 2017; 12(2):e0172364. PubMed ID: 28212447
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
[TBL] [Abstract][Full Text] [Related]
37. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
39. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
40. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
